These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31324230)

  • 1. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.
    Zhang J; Sun W; Lin J; Tian Y; Ma L; Zhang L; Zhu Y; Qiu W
    BMC Infect Dis; 2019 Jul; 19(1):645. PubMed ID: 31324230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
    Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
    Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
    Maghrabi HME; Elmowafy AY; Refaie AF; Elbasiony MA; Shiha GE; Rostaing L; Bakr MA
    Int Urol Nephrol; 2019 Dec; 51(12):2295-2304. PubMed ID: 31531807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
    Jadoul M; Martin P
    Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 Mar; 36(2):137-140. PubMed ID: 28345112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.
    Reese PP; Abt PL; Blumberg EA; Van Deerlin VM; Bloom RD; Potluri VS; Levine M; Porrett P; Sawinski D; Nazarian SM; Naji A; Hasz R; Suplee L; Trofe-Clark J; Sicilia A; McCauley M; Gentile C; Smith J; Niknam BA; Bleicher M; Reddy KR; Goldberg DS
    Ann Intern Med; 2018 Sep; 169(5):273-281. PubMed ID: 30083748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
    Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
    Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
    Nookala AU; Crismale J; Schiano T; Te H; Ahn J; Robertazzi S; Rodigas C; Satoskar R; Kc M; Hassan M; Smith C
    Clin Transplant; 2018 Mar; 32(3):e13198. PubMed ID: 29323755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
    Gendia M; Lampertico P; Alfieri CM; D'Ambrosio R; Gandolfo MT; Campise MR; Fabrizi F; Messa P
    Transpl Int; 2019 May; 32(5):493-501. PubMed ID: 30580473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil.
    Pacheco LS; Ventura PE; Kist R; Garcia VD; Meinerz G; Tovo CV; Cantisani GPC; Zanotelli ML; Mucenic M; Keitel E
    Rev Inst Med Trop Sao Paulo; 2023; 65():e59. PubMed ID: 38055377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.